bluebird bio
BLUE
#9803
Rank
โ‚ฌ41.8 M
Marketcap
4,27ย โ‚ฌ
Share price
0.00%
Change (1 day)
-77.85%
Change (1 year)

Revenue for bluebird bio (BLUE)

Revenue in 2025 (TTM): โ‚ฌ97.32 Million

According to bluebird bio 's latest financial reports the company's current revenue (TTM ) is โ‚ฌ89.27 Million. In 2024 the company made a revenue of โ‚ฌ80.53 Million an increase over the revenue in the year 2023 that were of โ‚ฌ26.68 Million. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for bluebird bio from 2012 to 2025

Annual revenue

Year Revenue Change
2025 (TTM) โ‚ฌ97.32 M20.85%
2024 โ‚ฌ80.53 M201.83%
2023 โ‚ฌ26.68 M695.5%
2022 โ‚ฌ3.35 M-110.2%
2021 -โ‚ฌ32.87 Million-116.12%
2020 โ‚ฌ0.20 B411.17%
2019 โ‚ฌ39.87 M-16.41%
2018 โ‚ฌ47.7 M61.58%
2017 โ‚ฌ29.52 M404.58%
2016 โ‚ฌ5.85 M-54.56%
2015 โ‚ฌ12.87 M-38.39%
2014 โ‚ฌ20.9 M43.03%
2013 โ‚ฌ14.61 M5585.29%
2012 โ‚ฌ0.25 M

Revenue for similar companies or competitors

Company Revenue Revenue differencediff. Country
BioMarin Pharmaceutical
BMRN
โ‚ฌ2.65 B 2,876.55%๐Ÿ‡บ๐Ÿ‡ธ USA
Acceleron Pharma
XLRN
โ‚ฌ96.85 M 8.48%๐Ÿ‡บ๐Ÿ‡ธ USA
Sanofi
SNY
โ‚ฌ40.81 B 45,620.93%๐Ÿ‡ซ๐Ÿ‡ท France
Sangamo Therapeutics
SGMO
โ‚ฌ28.23 M-68.37%๐Ÿ‡บ๐Ÿ‡ธ USA
Merck
MRK
โ‚ฌ55.17 B 61,696.51%๐Ÿ‡บ๐Ÿ‡ธ USA
GlycoMimetics
GLYC
N/AN/A๐Ÿ‡บ๐Ÿ‡ธ USA